What class is eplerenone in?
Eplerenone is a prescription medicine in the mineralocorticoid receptor antagonist (MRA) class, also called a potassium-sparing diuretic because it can help the body get rid of sodium and water without causing the same level of potassium loss as many other diuretics.
How does the eplerenone “class” work in the body?
As an MRA, eplerenone blocks the effects of aldosterone on the mineralocorticoid receptor. That action reduces sodium reabsorption in the kidneys, which lowers blood pressure and can help in certain types of heart disease. Because it blocks aldosterone’s potassium-wasting effect, eplerenone can raise potassium levels.
What other drugs are in the same class as eplerenone?
Eplerenone is part of the broader mineralocorticoid receptor antagonist family. Another well-known MRA is spironolactone. (They are related, but not identical in side-effect profiles and clinical use.)
What patient risks are tied to the MRA class?
A key class-related risk is hyperkalemia (high potassium). Patients taking eplerenone often need monitoring of potassium and kidney function, especially if they also use other medicines that raise potassium or have chronic kidney disease.
Where does eplerenone fit vs “water pills” (diuretics)?
Eplerenone is often described as a potassium-sparing diuretic because of its MRA mechanism. That distinguishes it from loop diuretics (like furosemide) and thiazide diuretics (like hydrochlorothiazide), which commonly lower potassium.
Is eplerenone’s patent/exclusivity information available?
For patent and exclusivity background specific to eplerenone, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/